Abstract:Arsenic compounds, including arsenic trioxide (As2O3) and arsenic sulfide (As4S4), have recently been shown to be effective in the treatment of acute promyelocytic leukemia (APL). In vitro, As2O3 exerts a dosedependent dual effect: it triggers apoptosis at relatively high concentrations (0.5 to 2.0 μmol/L) and induces partial differentiation at low concentrations (0.1 to 0.5 μmmol/L). The apoptosis-inducing effect is associated with the collapse of mitochondrial transmembrane potentials in a thiol-dependent manner, whereas the retinoic acid signaling is required for APL cell differentiation. As2O3 over a wide range of concentrations (0.1 to 2.0 μmol/L) induces degradation of PML-RARα as well as the wild-type PML and enhances the acetylation of histone, a process important for the transcriptional activation of genes. In vivo, As2O3 induces a high complete remission (CR) rate in patients with both primary and relapsed APL (around 85% to 90%). Side effects, such as skin reaction, gastrointestinal symptoms, electrocardiographic (EKG) changes, neuropathy, and liver dysfunction, are mild to moderate in relapsed patients, and severe hepatic lesions have been found in some primary cases. After CR obtained in relapsed patients, chemotherapy in combination with As2O3 as postremission therapy has yielded better survival than treatment with As2O3 alone. This is in line with the observation that remission induction with As2O3 is not sufficient in most cases to obtain a molecular remission as judged by reverse-transcriptase polymerase chain reaction for PML-RARα fusion transcripts. The in vivo effect of As2O3 seems to be related to the expression of APL-specific PML-RARα oncoprotein, and a synergistic effect between As2O3 and ATRA has been shown in the APL mouse model. Besides As2O3, other arsenic compounds such as As4S4 also show a therapeutic effect in APL. Because the toxic effects of arsenic treatment in primary APL need to be investigated further, we propose use of ATRA as a first-line drug for remission induction in primary APL, whereas As2O3 can be incorporated into multidrug postremission therapy or used as rescue for relapsed APL patients.

Study on the Mechanism of Apoptosis-Related Gene PNAS-2 in APL Cells Treated by Arsenic Sulfide

[Mechanism of Tetra-Arsenic Tetra-Sulfide in Inducing Apoptosis of Acute Promyelocytic Leukemia Cells].

Arsenic Trioxide Induces Not Only Apoptosis but Also Autophagic Cell Death in Leukemia Cell Lines Via Up-Regulation of Beclin-1

Comparative Proteome Study of Apoptosis Induced by As4S4 in Retinoid Acid Resistant Human Acute Promyelocytic Leukemia NB4-R1 Cells

Correlation between expression of apoptosis-related gene pnas-2 and leukemia]

Gene Expression Profile Changes in NB4 Cells Induced by Arsenic Trioxide

[Effect of Arsenic Trioxide on the Expression of Apoptosis-Related Genes in NB4 Cells].

In Vitro Studies on Cellular and Molecular Mechanisms of Arsenic Trioxide (as2o3) in the Treatment of Acute Promyelocytic Leukemia: As2O3 Induces NB4 Cell Apoptosis with Downregulation of Bcl-2 Expression and Modulation of PML-RAR Alpha/pml Proteins

Investigation on the Effect of Arsenic Trioxide on the Apoptosis- associated Gene Expression Profile of NB4 Cells by Human Apoptosis and Cell Cycle Gene Array

[Experimental study of low dose arsenic trioxide in treatment of patients with acute promyelocytic leukemia].

Treatment of Acute Promyelocytic Leukemia with Arsenic Compounds: in Vitro and in Vivo Studies

Research on the cell apoptosis of leukemia Induced by arsenic sulfide.

Tetra-arsenic Tetra-Sulfide Induces Cell Cycle Arrest and Apoptosis in Retinoic Acid-Resistant Acute Promyelocytic Leukemia Cells

Arsenic-induced PML Targeting Onto Nuclear Bodies: Implications for the Treatment of Acute Promyelocytic Leukemia

Effect of tetra-arsenic tetra-sulfide on Caspase-3 activity in acute promyelocytic leukemia cells

Use Of Arsenic Trioxide (As2o3) In The Treatment Of Acute Promyelocytic Leukemia (Apl) .1. As2o3 Exerts Dose-Dependent Dual Effects On Apl Cells

Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide

Arsenic trioxide, a therapeutic agent for APL.

Tetra-arsenic Tetra-Sulfide Enhances NK-92MI Mediated Cellular Immunotherapy in All-Trans Retinoic Acid-Resistant Acute Promyelocytic Leukemia.

PNAS-2: a novel gene probably participating in leukemogenesis.

Study on gene expression changes of arsenic sulfide treated NB4 cells]